Literature DB >> 27106545

Evaluation of subclinical inflammation in familial Mediterranean fever patients: relations with mutation types and attack status: a retrospective study.

Fatih Mehmet Kelesoglu1, Erhan Aygun2, Nazli Kubra Okumus2, Ayşenur Ersoy2, Edanur Karapınar2, Nesibe Saglam2, Nur Gokce Aydın2, Beyza Betul Senay2, Sumeyye Gonultas2, Elif Sarisik2, Melike Zeynep Can2, Sirin Atay2, Dilruba Basbug2, Feyza Kubra Tiryaki2, Sena Ozer2, Rana Berru Durmus2, Fatih Orem2, Tugrul Atay3, Ahmet Acar4,5, Yasin Yilmaz6, Seyma Kaya2, Aylin Ciftkaya2, Zeynep Sarac2, Cagri Can Makar2, Basak Saracoglu2, Gafur Dogdu7, Rukiye Eker Omeroglu2.   

Abstract

Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease of childhood and adulthood. Development of systemic amyloidosis and frequent attack influence quality of life and survival. There is sporadic evidence indicating subclinical inflammation in patients with FMF. We aimed to assess subclinical inflammation using neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein (CRP) in pediatric patients with FMF in the attack-free period. In this retrospective study, we reviewed the files of all FMF patients in our pediatric rheumatology outpatient clinic in a tertiary center and enrolled those with sufficient clinical and laboratory data. We also enrolled 73 controls. We grouped the patients according to being in attack period or attack-free period. We compared CRP, NLR, PLR, and WBC (white blood cell) levels between different mutations and polymorphisms. We also compared patients in the attack period with those in attack-free period. We enrolled 61 patients in attack period, 509 patients in attack-free period, and 73 controls. There was no difference between patients with different mutations with respect to NLR or PLR levels in the attack-free period. However, CRP levels were higher in patients with homozygous exon 10 mutations, especially those with homozygous M694V mutations compared with other mutations. However, CRP levels were mostly normal in these patients. Our data are against the reported fact that patients with FMF have higher NLR or PLR levels in attack-free periods. However, CRP levels were higher in the presence of homozygous exon 10 mutations (in particular homozygous M694V mutations).

Entities:  

Keywords:  C-reactive protein; Familial Mediterranean fever; Neutrophil to lymphocyte ratio; Platelet to lymphocyte ratio; Subclinical inflammation

Mesh:

Substances:

Year:  2016        PMID: 27106545     DOI: 10.1007/s10067-016-3275-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  24 in total

1.  Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention.

Authors:  Mahmut Akpek; Mehmet Gungor Kaya; Yat Yin Lam; Omer Sahin; Deniz Elcik; Turgay Celik; Ali Ergin; Charles Michael Gibson
Journal:  Am J Cardiol       Date:  2012-05-18       Impact factor: 2.778

2.  Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill.

Authors:  R Zahorec
Journal:  Bratisl Lek Listy       Date:  2001       Impact factor: 1.278

3.  Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis.

Authors:  Basem Azab; Neil Jaglall; Jean Paul Atallah; Ari Lamet; Venkat Raja-Surya; Bachir Farah; Martin Lesser; Warren D Widmann
Journal:  Pancreatology       Date:  2011-09-28       Impact factor: 3.996

4.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

5.  Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Gareth Morris-Stiff; Carla Campbell; Rocio Lopez; Tarek Abu-Rajab Tamimi; Lisa Yerian; Nizar N Zein; Ariel E Feldstein
Journal:  Liver Int       Date:  2011-09-08       Impact factor: 5.828

Review 6.  Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.

Authors:  J Samuels; I Aksentijevich; Y Torosyan; M Centola; Z Deng; R Sood; D L Kastner
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

Review 7.  Familial Mediterranean fever.

Authors:  Aysin Bakkaloglu
Journal:  Pediatr Nephrol       Date:  2003-06-27       Impact factor: 3.714

8.  Late-onset disease is associated with a mild phenotype in children with familial Mediterranean fever.

Authors:  Semanur Özdel; Z Birsin Özçakar; Seda Şahin Kunt; Atilla H Elhan; Fatoş Yalçınkaya
Journal:  Clin Rheumatol       Date:  2016-02-03       Impact factor: 2.980

9.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

Authors:  W Chua; K A Charles; V E Baracos; S J Clarke
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

10.  Genetic Profile of Patients with Familial Mediterranean Fever (FMF): Single Center Experience at King Hussein Medical Center (KHMC).

Authors:  Lana Ayesh Habahbeh; Mansour Al Hiary; Samar F Al Zaben; Asim Al-Momani; Rame Khasawneh; Mervat Abu Mallouh; Hayab Farahat
Journal:  Med Arch       Date:  2015-12
View more
  3 in total

1.  Assessment of vascular damage in children and young adults with Familial Mediterranean Fever.

Authors:  Olga Vampertzi; Kyriaki Papadopoulou-Legbelou; Areti Triantafyllou; Nikolaos Koletsos; Sofia Alataki; Stella Douma; Efimia Papadopoulou-Alataki
Journal:  Rheumatol Int       Date:  2021-11-05       Impact factor: 2.631

2.  Nodular Lymphocyte-Predominant Hodgkin Lymphoma in a Patient with Familial Mediterranean Fever.

Authors:  Marina Belia; Asimina Papanikolaou; Panagiotis Skendros; Theodoros P Vassilakopoulos
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-07-01       Impact factor: 3.122

Review 3.  Familial Mediterranean Fever: Assessing the Overall Clinical Impact and Formulating Treatment Plans.

Authors:  Raffaele Manna; Donato Rigante
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-05-01       Impact factor: 3.122

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.